Compare ROG & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROG | ANIP |
|---|---|---|
| Founded | 1832 | 2001 |
| Country | United States | United States |
| Employees | N/A | 897 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | ROG | ANIP |
|---|---|---|
| Price | $106.56 | $79.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $85.00 | ★ $107.33 |
| AVG Volume (30 Days) | 160.0K | ★ 503.9K |
| Earning Date | 02-17-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.67 |
| Revenue | $801,500,000.00 | ★ $826,880,000.00 |
| Revenue This Year | N/A | $44.19 |
| Revenue Next Year | $7.31 | $11.25 |
| P/E Ratio | ★ N/A | $47.97 |
| Revenue Growth | N/A | ★ 48.87 |
| 52 Week Low | $51.43 | $54.10 |
| 52 Week High | $107.05 | $99.50 |
| Indicator | ROG | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 68.53 | 43.21 |
| Support Level | $96.23 | $78.38 |
| Resistance Level | $107.05 | $83.80 |
| Average True Range (ATR) | 3.18 | 2.60 |
| MACD | 0.59 | -0.21 |
| Stochastic Oscillator | 87.63 | 15.78 |
Rogers Corporation designs develop and manufacture engineered materials and components for sale to original equipment manufacturers and component suppliers. The firm operates in three business segments: Advanced Electronics Solutions, which manufactures circuit materials for applications in communications infrastructure, automotive, and consumer electronics markets; elastomeric material solutions, which provide cushioning, sealing, and impact protection in automotive, transportation, and construction applications; and Other, which consists of elastomer components for applications in the general industrial market, as well as elastomer floats for level sensing in fuel tanks, motors, and storage tanks applications in the general industrial and automotive markets.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.